ArticleRheumatology and therapy2026
Two-Year Treatment Persistence and Effectiveness of Ixekizumab in Psoriatic Arthritis in Italian Clinical Practice: Results from the ROUTE-IXE Study.
Article in Rheumatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRandomised controlled trials have demonstrated the efficacy and safety of ixekizumab as a treatment for active psoriatic arthritis (PsA), and real-world evidence on long-term persistence and effectiveness is emerging. This study aimed to characterise ixekizumab use in the Italian routine clinical setting and provide insights into its persistence and effectiveness, complementing real-world evidence from single-country cohorts and multinational studies.
methodsThis descriptive, multicentre, retrospective study was conducted in Italy in adult patients with PsA who received a first prescription of ixekizumab after January 2021 and had a minimum of three subsequent evaluations. The primary objective was to describe treatment persistence at week 104. Secondary objectives aimed to describe patients' demographic and clinical characteristics and evaluate treatment persistence and effectiveness at weeks 12, 24, 52 and 104.
resultsA total of 204 patients, of whom 88 (43.1%) were male and 116 (56.9%) were female, were eligible for inclusion in the study. The mean (standard deviation) age was 55.8 (11.0) years. Comorbidities were present in 66.7% (n = 136) of patients, with the majority being cardiometabolic disorders. The median (interquartile range) disease duration was 5.3 (2.4-12.2) years. Peripheral joint involvement was the most common PsA manifestation (66.7%, n = 136), followed by mixed symptoms (28.4%, n = 58) and axial-only symptoms (4.9%, n = 10). Most patients (74.5%, n = 152) had prior exposure to biologic therapy; most also presented with high or moderate disease activity (84.6%, n = 132). Treatment persistence at week 104 was 78.6% (n = 158), and the Kaplan-Meier estimate was 0.800 (95% confidence interval 0.736-0.850). Disease activity progressively improved. At week 104, 45.3% (n = 72) of patients had low disease activity, and 25.2% (n = 40) were in remission; 34.1% (n = 31) achieved very low disease activity, and, among patients with axial involvement, 61.9% (n = 26) had inactive or mild disease.
conclusionIxekizumab showed high 2-year treatment persistence and effectiveness in the treatment of patients with PsA and complex disease profiles, supporting its value in informing treatment decisions and optimising patient outcomes.
Indexed as
Identifiers
43007639What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.